The clinical study included 22 patients and aimed to evaluate the safety and efficacy of the company’s primary treatment, “Odronextamab,” in conjunction with chemotherapy for patients with diffuse large B-cell lymphoma (DLBCL).
“Odronextamab” is classified as a class of treatments known as bispecific antibodies, which are designed to bind to cancer cells and immune cells simultaneously, bringing them together to enable the immune system to eliminate cancer cells.
The company indicated that patients who received a 160 mg dose of this combination therapy showed a 100% complete response rate.
Large cell lymphoma is a rapidly spreading type of blood cancer that affects the lymphatic system, a network of tissues, vessels, and organs that help the body fight infection. This type of cancer is characterized by changes in B cells, a type of white blood cell.
Afia Choudry, Head of Global Program at Regeneron, stated: “Part of our focus here at Regeneron is on developing highly effective bispecific drugs that do not require a very heavy additional mix of drugs to be combined because their activity in itself is very strong.”
